 |
PDBsum entry 2q9f
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Oxidoreductase
|
PDB id
|
|
|
|
2q9f
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.1.14.14.25
- cholesterol 24-hydroxylase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
cholesterol + reduced [NADPH--hemoprotein reductase] + O2 = (24S)- hydroxycholesterol + oxidized [NADPH--hemoprotein reductase] + H2O + H+
|
 |
 |
 |
 |
 |
cholesterol
Bound ligand (Het Group name = )
matches with 87.50% similarity
|
+
|
reduced [NADPH--hemoprotein reductase]
|
+
|
O2
|
=
|
(24S)- hydroxycholesterol
|
+
|
oxidized [NADPH--hemoprotein reductase]
|
+
|
H2O
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
Cofactor:
|
 |
Heme-thiolate
|
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
105:9546-9551
(2008)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain.
|
|
N.Mast,
M.A.White,
I.Bjorkhem,
E.F.Johnson,
C.D.Stout,
I.A.Pikuleva.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
By converting cholesterol to 24S-hydroxycholesterol, cytochrome P450 46A1
(CYP46A1) initiates the major pathway for cholesterol removal from the brain.
Two crystal structures of CYP46A1 were determined. First is the 1.9-A structure
of CYP46A1 complexed with a high-affinity substrate cholesterol 3-sulfate
(CH-3S). The second structure is that of the substrate-free CYP46A1 at 2.4-A
resolution. CH-3S is bound in the productive orientation and occupies the entire
length of the banana-shaped hydrophobic active-site cavity. A unique helix B'-C
loop insertion (residues 116-120) contributes to positioning cholesterol for
oxygenation catalyzed by CYP46A1. A comparison with the substrate-free structure
reveals substantial substrate-induced conformational changes in CYP46A1 and
suggests that structurally distinct compounds could bind in the enzyme active
site. In vitro assays were performed to characterize the effect of different
therapeutic agents on cholesterol hydroxylase activity of purified full-length
recombinant CYP46A1, and several strong inhibitors and modest coactivators of
CYP46A1 were identified. Structural and biochemical data provide evidence that
CYP46A1 activity could be altered by exposure to some therapeutic drugs and
potentially other xenobiotics.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
CYP46A1 active site. (a) The composite-omit 2|F[o]|−|F[c]|
electron density map (green mesh) contoured at 1.5σ around the
heme (in pink) and CH-3S (in yellow). Amino acid residues (in
cyan) within 4 Å of CH-3S are shown. The heme iron and
water molecule 732 are represented as big brown and small red
spheres, respectively. The oxygen, nitrogen, and sulfur atoms
are in red, blue, and orange, respectively. Dashed cyan lines
indicate hydrogen bonds. Residues forming a circular scaffold
are labeled in red. (b) Enlarged view of the active site around
the sulfate anion of CH-3S and (c) in the vicinity of the heme
iron. Dashed gray lines connect the C24 and C25 of CH-3S and the
heme iron.
|
 |
Figure 2.
Superposition of CH-3S-bound CYP46A1 structure (colored from
blue at the N terminus to red at the C terminus) and vitamin
D[3]-bound CYP2R1 structure (in wheat) shown in stereoview.
CH-3S and vitamin D[3] are in yellow and cyan, respectively, and
heme is in pink in CYP46A1 and in light pink in CYP2R1.
|
 |
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
N.M.DeVore,
and
E.E.Scott
(2012).
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
|
| |
Nature,
482,
116-119.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.Y.Rhieu,
A.J.Annalora,
R.M.Gathungu,
P.Vouros,
M.R.Uskokovic,
I.Schuster,
G.T.Palmore,
and
G.S.Reddy
(2011).
A new insight into the role of rat cytochrome P450 24A1 in metabolism of selective analogs of 1α,25-dihydroxyvitamin D₃.
|
| |
Arch Biochem Biophys,
509,
33-43.
|
 |
|
|
|
|
 |
A.G.Warrilow,
C.M.Martel,
J.E.Parker,
N.Melo,
D.C.Lamb,
W.D.Nes,
D.E.Kelly,
and
S.L.Kelly
(2010).
Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51).
|
| |
Antimicrob Agents Chemother,
54,
4235-4245.
|
 |
|
|
|
|
 |
A.J.Annalora,
D.B.Goodin,
W.X.Hong,
Q.Zhang,
E.F.Johnson,
and
C.D.Stout
(2010).
Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism.
|
| |
J Mol Biol,
396,
441-451.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
G.I.Lepesheva,
H.W.Park,
T.Y.Hargrove,
B.Vanhollebeke,
Z.Wawrzak,
J.M.Harp,
M.Sundaramoorthy,
W.D.Nes,
E.Pays,
M.Chaudhuri,
F.Villalta,
and
M.R.Waterman
(2010).
Crystal structures of Trypanosoma brucei sterol 14alpha-demethylase and implications for selective treatment of human infections.
|
| |
J Biol Chem,
285,
1773-1780.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.V.Goldstone,
A.G.McArthur,
A.Kubota,
J.Zanette,
T.Parente,
M.E.Jönsson,
D.R.Nelson,
and
J.J.Stegeman
(2010).
Identification and developmental expression of the full complement of Cytochrome P450 genes in Zebrafish.
|
| |
BMC Genomics,
11,
643.
|
 |
|
|
|
|
 |
M.Shafaati,
N.Mast,
O.Beck,
R.Nayef,
G.Y.Heo,
L.Björkhem-Bergman,
D.Lütjohann,
I.Björkhem,
and
I.A.Pikuleva
(2010).
The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo.
|
| |
J Lipid Res,
51,
318-323.
|
 |
|
|
|
|
 |
T.C.Pochapsky,
S.Kazanis,
and
M.Dang
(2010).
Conformational plasticity and structure/function relationships in cytochromes P450.
|
| |
Antioxid Redox Signal,
13,
1273-1296.
|
 |
|
|
|
|
 |
D.W.Russell,
R.W.Halford,
D.M.Ramirez,
R.Shah,
and
T.Kotti
(2009).
Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain.
|
| |
Annu Rev Biochem,
78,
1017-1040.
|
 |
|
|
|
|
 |
K.J.McLean,
P.Lafite,
C.Levy,
M.R.Cheesman,
N.Mast,
I.A.Pikuleva,
D.Leys,
and
A.W.Munro
(2009).
The Structure of Mycobacterium tuberculosis CYP125: molecular basis for cholesterol binding in a P450 needed for host infection.
|
| |
J Biol Chem,
284,
35524-35533.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.Mast,
W.L.Liao,
I.A.Pikuleva,
and
I.V.Turko
(2009).
Combined use of mass spectrometry and heterologous expression for identification of membrane-interacting peptides in cytochrome P450 46A1 and NADPH-cytochrome P450 oxidoreductase.
|
| |
Arch Biochem Biophys,
483,
81-89.
|
 |
|
|
|
|
 |
W.L.Liao,
N.G.Dodder,
N.Mast,
I.A.Pikuleva,
and
I.V.Turko
(2009).
Steroid and protein ligand binding to cytochrome P450 46A1 as assessed by hydrogen-deuterium exchange and mass spectrometry.
|
| |
Biochemistry,
48,
4150-4158.
|
 |
|
|
|
|
 |
I.A.Pikuleva
(2008).
Cholesterol-metabolizing cytochromes P450: implications for cholesterol lowering.
|
| |
Expert Opin Drug Metab Toxicol,
4,
1403-1414.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |